Published: 2022-08-24

Koebner’s phenomena observed in patient receiving adalimumab in psoriasis

Jaydeep H. Rathod, Dhawait M. Shukla, Devang A. Rana, Supriya D. Malhotra


Koebner’s phenomena, first described in 1877 as the appearance of psoriatic lesions in the uninvolved skin of psoriatic patients as a consequence of trauma. Koebner phenomena has been associated with the use of biological response modifiers. The development of the anti-TNF therapies is a milestone in the therapy of rheumatic diseases. As in all new treatment opportunities it is of concern whether all potential undesired side effects have been evaluated. We report a case involving a 31-year-old young male patient diagnosed with psoriasis and psoriatic arthritis (PsA) since a year, who received Adalimumab as part of his treatment and developed Koebner’s phenomena.



Koebner’s phenomena, Psoriasis, PsA, Adalimumab

Full Text:



Ji YZ, Liu SR. Koebner phenomenon leading to the formation of new psoriatic lesions: evidences and mechanisms. Bioscience reports. 2019;39(12).

Li SJ, Perez-Chada LM, Merola JF. TNF inhibitor-induced psoriasis: proposed algorithm for treatment and management. J Psoriasis Psoriatic Arthritis. 2019;4(2):70-80.

Ahad T, Agius E. The Koebner phenomenon. Bri J Hospital Med. 2015;76(11):C170-2.

Joel D. Taurog. The Spondyloarthritides. Jameson JL, Kasper DL, Longo DL, Fauci AS, Hauser SL, Loscalzo J. Harrison's principles of internal medicine 20th edition. 2018.

Weiss G, Shemer A, Trau H. The Koebner phenomenon: review of the literature. J Eur Academy Dermatol Venereol. 2002;16(3):241-8.

Krensky AM, Azzi JR, Hafler DA. Immunosuppressants and Tolerogens. In: Brunton LB, Lazo JS, Parker KL, eds.Goodman and Gilman's The Pharmacological Basis of Therapeutics. 13th ed. New York, NY: McGraw-Hill. 2018.

Scheinfeld N. A comprehensive review and evaluation of the side effects of the tumor necrosis factor alpha blockers etanercept, infliximab and adalimumab. J dermatological Treatment. 2004;15(5):280-94.

Ueki H. Koebner phenomenon in lupus erythematosus with special consideration of clinical findings. Autoimmunity Rev. 2005;4(4):219-23.